Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.72−0.18 (-6.37%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
Recursion Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Recursion Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$544.01M. For fiscal 2025 it was -$648.13M. The highest annual figure on record is -$62.44M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$648.13M | – |
| FY2024 | Dec 31, 2024 | -$479.00M | – |
| FY2023 | Dec 31, 2023 | -$350.06M | – |
| FY2022 | Dec 31, 2022 | -$245.73M | – |
| FY2021 | Dec 31, 2021 | -$182.78M | – |
| FY2020 | Dec 31, 2020 | -$84.62M | – |
| FY2019 | Dec 31, 2019 | -$62.44M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$134.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$128.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$108.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$172.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$176.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$191.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$183.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$98.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$100.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$96.34M | – |
| Q4 FY2023 | Dec 31, 2023 | -$98.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$99.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$81.72M | – |
| Q1 FY2023 | Mar 31, 2023 | -$69.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$60.98M | – |
| Q3 FY2022 | Sep 30, 2022 | -$62.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$66.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$55.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$64.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$46.40M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.93M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$22.47M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.34M | – |
See a number that looks wrong?